EP Patent

EP2902018A1 — Intraocular pressure reduction with intracameral bimatoprost implants

Assigned to Allergan Inc · Expires 2015-08-05 · 11y expired

What this patent protects

The present invention relates to intraocular implants that are useful for treating ocular conditions in a patient.

USPTO Abstract

The present invention relates to intraocular implants that are useful for treating ocular conditions in a patient.

Drugs covered by this patent

Travatan (TRAVOPROST)

Patent Metadata

Patent number: EP2902018A1
Jurisdiction: EP
Classification: —
Expires: 2015-08-05
Drug substance claim: No
Drug product claim: No
Assignee: Allergan Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.